<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Etanercept</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Etanercept">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Etanercept</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Etanercept</b>, sold under the brand name <b>Enbrel</b> among others, is a biopharmaceutical that treats autoimmune diseases by interfering with tumor necrosis factor (TNF, a soluble inflammatory cytokine) by acting as a TNF inhibitor. It has U.S. F.D.A. approval to treat rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. TNF-alpha is the "master regulator" of the inflammatory (immune) response in many organ systems. Autoimmune diseases are caused by an overactive immune response. Etanercept has the potential to treat these diseases by inhibiting TNF-alpha.<span class="mw-ref" id="cite_ref-titleTNF_defined_as_a_therapeutic_target_for_rheumatoid_arthritis_and_other_autoimmune_diseases_-_Nature_Medicine_2-0"><a href="#cite_note-titleTNF_defined_as_a_therapeutic_target_for_rheumatoid_arthritis_and_other_autoimmune_diseases_-_Nature_Medicine-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>

<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Etanercept</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Enbrel.jpg" tppabs="https://ptable.com/wiki/compounds/I/m/Enbrel.jpg" data-file-width="153" data-file-height="422" data-file-type="bitmap" height="422" width="153"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Enbrel, Benepali, Erelzi, others</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Other names</th><td>etanercept-szzs, etanercept-ykro</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/etanercept.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/etanercept.html'" tppabs="https://www.drugs.com/monograph/etanercept.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a602013.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a602013.html'" tppabs="https://medlineplus.gov/druginfo/meds/a602013.html" class="external text external">a602013</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Etanercept  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Etanercept'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Etanercept" class="external text external">by INN</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span>DailyMed:<span>&nbsp;</span><span><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Etanercept  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Etanercept'" tppabs="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Etanercept" class="external text external">Etanercept</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>D<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_1-0"><a href="#cite_note-Drugs.com_pregnancy-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>N (Not classified yet)<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_1-1"><a href="#cite_note-Drugs.com_pregnancy-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>Subcutaneous injection</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>L04AB01<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L04AB01  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L04AB01'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L04AB01" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>S4 (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">UK</abbr>:</small><span> </span>POM (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>58–76% (SC)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>Reticuloendothelial system (speculative)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>70–132 hours</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=185243-69-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=185243-69-0'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=185243-69-0" class="external text external">185243-69-0</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem<span> </span><span style="font-weight:normal"><abbr>SID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=10099  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=10099'" tppabs="https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=10099" class="external text external">10099</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00005  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00005'" tppabs="https://www.drugbank.ca/drugs/DB00005" class="external text external">DB00005</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li>none</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=OP401G7OJC  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=OP401G7OJC'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=OP401G7OJC" class="external text external">OP401G7OJC</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D00742  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D00742'" tppabs="https://www.kegg.jp/entry/D00742" class="external text external">D00742</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201572  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201572'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201572" class="external text external">ChEMBL1201572</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID8040850  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID8040850'" tppabs="https://comptox.epa.gov/dashboard/DTXSID8040850" class="external text external">DTXSID8040850</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.224.383  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.224.383'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.224.383" class="external text external">100.224.383</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>2224</sub><span>H</span><sub>3475</sub><span>N</span><sub>621</sub><span>O</span><sub>698</sub><span>S</span><sub>36</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">51<span style="margin-left:.25em;">235</span>.07</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr></tbody></table>

<p>Etanercept is a fusion protein produced by recombinant DNA. It fuses the TNF receptor to the constant end of the IgG1 antibody. First, the developers isolated the DNA sequence that codes the human gene for soluble TNF receptor 2, which is a receptor that binds to tumor necrosis factor-alpha. Second, they isolated the DNA sequence that codes the human gene for the Fc end of immunoglobulin G1 (IgG1). Third, they linked the DNA for TNF receptor 2 to the DNA for IgG1 Fc. Finally, they expressed the linked DNA to produce a protein that links the protein for TNF receptor 2 to the protein for IgG1 Fc.
The prototypic fusion protein was first synthesized and shown to be highly active and unusually stable as a modality for blockade of TNF in vivo in the early 1990s by Bruce A. Beutler, an academic researcher then at the University of Texas Southwestern Medical Center at Dallas, and his colleagues.<span class="mw-ref" id="cite_ref-3"><a href="#cite_note-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-4"><a href="#cite_note-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>

<p>These investigators also patented the protein,<span class="mw-ref" id="cite_ref-5"><a href="#cite_note-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> selling all rights to its use to Immunex, a biotechnology company that was acquired by Amgen in 2002.<span class="mw-ref" id="cite_ref-title||_DukeMedNews_||_Arthritis_Drug_Effective_for_Depression_in_Psoriasis_Sufferers_6-0"><a href="#cite_note-title||_DukeMedNews_||_Arthritis_Drug_Effective_for_Depression_in_Psoriasis_Sufferers-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>

<p>It is a large molecule, with a molecular weight of 150 kDa, that binds to TNFα and decreases its role in disorders involving excess inflammation in humans and other animals, including autoimmune diseases such as ankylosing spondylitis,<span class="mw-ref" id="cite_ref-pmid17389658_7-0"><a href="#cite_note-pmid17389658-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span> juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and, potentially, in a variety of other disorders mediated by excess TNFα. It is on the World Health Organization's List of Essential Medicines.<span class="mw-ref" id="cite_ref-WHO21st_8-0"><a href="#cite_note-WHO21st-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    
<p>In the United States etanercept is indicated for:</p>
<ul><li>Moderate to Severe Rheumatoid Arthritis (RA) (Nov 1998)<span class="mw-ref" id="cite_ref-9"><a href="#cite_note-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></li>
<li>Moderate to Severe Polyarticular Juvenile Rheumatoid Arthritis (May 1999)<span class="mw-ref" id="cite_ref-10"><a href="#cite_note-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></li>
<li>Psoriatic Arthritis (Jan 2002)<span class="mw-ref" id="cite_ref-11"><a href="#cite_note-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span></li>
<li>Ankylosing Spondylitis (AS) (July 2003)<span class="mw-ref" id="cite_ref-12"><a href="#cite_note-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span><span class="mw-ref" id="cite_ref-13"><a href="#cite_note-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span></li>
<li>Moderate to Severe Plaque Psoriasis (April 2004)<span class="mw-ref" id="cite_ref-14"><a href="#cite_note-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span></li></ul>

<p>In the European Union etanercept is indicated to treat:</p>
<ul><li>moderate to severe active rheumatoid arthritis<span class="mw-ref" id="cite_ref-Enbrel_EPAR_15-0"><a href="#cite_note-Enbrel_EPAR-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span></li>
<li>severe, active and progressive rheumatoid arthritis<span class="mw-ref" id="cite_ref-Enbrel_EPAR_15-1"><a href="#cite_note-Enbrel_EPAR-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span></li>
<li>juvenile idiopathic arthritis<span class="mw-ref" id="cite_ref-Enbrel_EPAR_15-2"><a href="#cite_note-Enbrel_EPAR-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span></li>
<li>polyarthritis (rheumatoid-factor-positive or -negative) and extended oligoarthritis in children and adolescents<span class="mw-ref" id="cite_ref-Enbrel_EPAR_15-3"><a href="#cite_note-Enbrel_EPAR-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span></li>
<li>active and progressive psoriatic arthritis<span class="mw-ref" id="cite_ref-Enbrel_EPAR_15-4"><a href="#cite_note-Enbrel_EPAR-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span></li>
<li>enthesitis-related arthritis</li>
<li>axial spondyloarthritis<span class="mw-ref" id="cite_ref-Enbrel_EPAR_15-5"><a href="#cite_note-Enbrel_EPAR-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span></li>
<li>severe active ankylosing spondylitis<span class="mw-ref" id="cite_ref-Enbrel_EPAR_15-6"><a href="#cite_note-Enbrel_EPAR-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span></li>
<li>severe non-radiographic axial spondyloarthritis<span class="mw-ref" id="cite_ref-Enbrel_EPAR_15-7"><a href="#cite_note-Enbrel_EPAR-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span></li>
<li>moderate to severe plaque psoriasis<span class="mw-ref" id="cite_ref-Enbrel_EPAR_15-8"><a href="#cite_note-Enbrel_EPAR-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span></li>
<li>chronic severe plaque psoriasis pediatric plaque psoriasis<span class="mw-ref" id="cite_ref-Enbrel_EPAR_15-9"><a href="#cite_note-Enbrel_EPAR-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span></li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Safety">Safety</h2></summary>
    

<p>On May 2, 2008, the FDA placed a black box warning on etanercept due to a number of serious infections associated with the drug.<span class="mw-ref" id="cite_ref-Wyeth_and_Amgen_16-0"><a href="#cite_note-Wyeth_and_Amgen-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span>  Serious infections and sepsis, including fatalities, have been reported with the use of etanercept including reactivation of latent tuberculosis and hepatitis B infections.<span class="mw-ref" id="cite_ref-FDAReport_17-0"><a href="#cite_note-FDAReport-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span><span class="mw-ref" id="cite_ref-titlePrescribing_Information_-_ENBREL_18-0"><a href="#cite_note-titlePrescribing_Information_-_ENBREL-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span></p>

<p>There has also been a report of strongyloides hyperinfection after use of etanercept.<span class="mw-ref" id="cite_ref-19"><a href="#cite_note-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Mechanism_of_action">Mechanism of action</h2></summary>
    
<p>It reduces the effect of naturally present TNF, and hence is a TNF inhibitor, functioning as a decoy receptor that binds to TNF.<span class="mw-ref" id="cite_ref-20"><a href="#cite_note-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span></p>

<p>Tumor necrosis factor-alpha (TNFα) is a cytokine produced by lymphocytes and macrophages, two types of white blood cells. It mediates the immune response by attracting additional white blood cells to sites of inflammation and through additional molecular mechanisms that initiate and amplify inflammation. Inhibition of its action by etanercept reduces the inflammatory response, which is especially useful for treating autoimmune diseases.</p>

<p>There are two types of TNF receptors: those found embedded in white blood cells that respond to TNF by releasing other cytokines, and <i>soluble</i> TNF receptors that are used to deactivate TNF and blunt the immune response. In addition, TNF receptors are found on the surface of virtually all nucleated cells (red blood cells, which are not nucleated, do not contain TNF receptors on their surface). Etanercept mimics the inhibitory effects of naturally occurring soluble TNF receptors, the difference being that etanercept, because it is a fusion protein rather than a simple TNF receptor, has a greatly extended half-life in the bloodstream, and therefore a more profound and long-lasting biologic effect than a naturally occurring soluble TNF receptor.<span class="mw-ref" id="cite_ref-pmid16135466_21-0"><a href="#cite_note-pmid16135466-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Structure">Structure</h2></summary>
    
<p>Etanercept is made from the combination of two naturally occurring soluble human 75-kilodalton TNF receptors linked to an Fc portion of an IgG1.<span class="mw-ref" id="cite_ref-pmid1936291_22-0"><a href="#cite_note-pmid1936291-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> The effect is an artificially engineered dimeric fusion protein.<span class="mw-ref" id="cite_ref-pmid1936291_22-1"><a href="#cite_note-pmid1936291-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> Etanercept is a complex molecule containing 6 N-glycans, up to 14 O-glycans and 29 disulfide bridge structures.<span class="mw-ref" id="cite_ref-23"><a href="#cite_note-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span><span class="mw-ref" id="cite_ref-24"><a href="#cite_note-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span><span class="mw-ref" id="cite_ref-:0_25-0"><a href="#cite_note-:0-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    
<p>The fusion protein was developed by Bruce A. Beutler, an academic researcher then at the University of Texas Southwestern Medical Center at Dallas, and colleagues, who patented it and sold the rights to Immunex. The first etanercept-related patent was filed by Immunex on September 5, 1989.<span class="mw-ref" id="cite_ref-26"><a href="#cite_note-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span></p>

<p>Etanercept was approved for use in the United States in November 1998.<span class="mw-ref" id="cite_ref-27"><a href="#cite_note-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span></p>

<p>Etanercept was approved for use in the European Union in February 2000.<span class="mw-ref" id="cite_ref-Enbrel_EPAR_15-10"><a href="#cite_note-Enbrel_EPAR-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Society_and_culture">Society and culture</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Marketing">Marketing</h3></summary>
    
<p>In North America, etanercept is marketed by Amgen under the trade name Enbrel in two separate formulations, one in powder form, the other as a pre-mixed liquid. Wyeth (now part of Pfizer) was the sole marketer of Enbrel outside North America excluding Japan where Takeda Pharmaceuticals markets the drug.</p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Economics">Economics</h3></summary>
    
<p>The U.S. retail price of Enbrel has risen over time.  In 2008, the cost of Enbrel was $1,500 per month or $18,000 per year.<span class="mw-ref" id="cite_ref-28"><a href="#cite_note-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span>  By 2011, the cost had exceeded $20,000 per year.<span class="mw-ref" id="cite_ref-NYTAmgen2011_29-0"><a href="#cite_note-NYTAmgen2011-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span><span class="mw-ref" id="cite_ref-30"><a href="#cite_note-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span>  In 2013, a survey by the International Federation of Health Plans (IFHP) found that the average U.S. cost for Enbrel was $2,225 per month, or $26,700 per year.<span class="mw-ref" id="cite_ref-IFHP2013_31-0"><a href="#cite_note-IFHP2013-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span>  The IFHP report also found wide variation in prices charged to various U.S. health plans, between $1,946 per month at the 25th percentile and $4,006 per month at the 95th percentile.<span class="mw-ref" id="cite_ref-IFHP2013_31-1"><a href="#cite_note-IFHP2013-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span></p>

<p>Enbrel is more expensive in the U.S. than in other countries.<span class="mw-ref" id="cite_ref-IFHP2013_31-2"><a href="#cite_note-IFHP2013-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span>  As of 2013, average monthly costs in surveyed nations ranged from $1,017 in Switzerland to $1,646 in Canada, compared to an average monthly cost of $2,225 per month in the U.S.<span class="mw-ref" id="cite_ref-IFHP2013_31-3"><a href="#cite_note-IFHP2013-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span></p>

<p>Amgen sells Enbrel within the U.S. and Canada, while Pfizer, Inc. sells the drug outside of the U.S. and Canada.<span class="mw-ref" id="cite_ref-NYTAmgen2011_29-1"><a href="#cite_note-NYTAmgen2011-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span>  Sales within the U.S. and Canada were $3.5 billion in 2010.<span class="mw-ref" id="cite_ref-NYTAmgen2011_29-2"><a href="#cite_note-NYTAmgen2011-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span>  Sales of Enbrel outside the U.S. and Canada were $3.3 billion in 2010.<span class="mw-ref" id="cite_ref-32"><a href="#cite_note-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Patents">Patents</h3></summary>
    
<p>The patent on Enbrel was originally set to expire on October 23, 2012,<span class="mw-ref" id="cite_ref-33"><a href="#cite_note-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span> but, in the United States, a second patent, granting exclusivity for another 16 years, has been granted.<span class="mw-ref" id="cite_ref-34"><a href="#cite_note-34" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span></p>

<p>Before the extension it seemed unlikely that a generic would have been available. As a biologic, etanercept is subject to different laws from those applicable to chemical formulations. Currently many countries do not permit the manufacture of generic biologics. However, the European Union and the United States (<a href="javascript:if(confirm('https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/'" tppabs="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/" class="external text external">Biologics Price Competition and Innovation Act of 2009</a>) do currently have in place a system to approve generic biologics (biosimilars) which "requires mandatory clinical testing and periodic review".<span class="mw-ref" id="cite_ref-35"><a href="#cite_note-35" style="counter-reset: mw-Ref 35;"><span class="mw-reflink-text">[35]</span></a></span></p>

<p>In April 2013, the Indian pharma major Cipla made an announcement about launching the first biosimilar of Etanercept in India under the brand name 'Etacept' for the treatment of rheumatic disorders. The company's April 17, 2013 press release claimed that the biosimilar will cost 30% less as compared to the innovator.<span class="mw-ref" id="cite_ref-36"><a href="#cite_note-36" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></span></p>

<p>In January 2015, Samsung and Biogen's joint venture "Samsung Bioepis" successfully submitted <b>Benepali</b>, a biosimilar version of the drug, for review to the European Medicines Agency (EMA), and announced that it will seek regulatory approvals in other territories as well. Later the same year, the European Medicines Agency also accepted Sandoz’s application for review of its etanercept biosimilar <b>Erelzi</b> which will be marketed by Novartis.<span class="mw-ref" id="cite_ref-37"><a href="#cite_note-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span></p>

<p>In the U.S., Sandoz submitted a biologics license application (BLA) for the proposed etanercept product "GP2015" in July 2016.  Upon acceptance of the first application process, the U.S. FDA reviewed data from European clinical trials and bio-analytical investigations, demonstrating the biosimilarity of GP2015 to the US-licensed Enbrel. Sandoz in 2009 tried to invalidate the patents held by Hoffman-La Roche/Immunex and exclusively licensed to Amgen but lost in federal court. Sandoz was then countersued by Amgen for patent infringements related to the methods of treating psoriasis and/or psoriatic arthritis. The case Immunex Corp. et al. vs. Sandoz Inc. et al., 16-cv-01118-CCC-JBC (D.N.J.) is pending.<span class="mw-ref" id="cite_ref-38"><a href="#cite_note-38" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Biosimilars">Biosimilars</h3></summary>
    


<p>In January 2016, Benpali was approved for use in the European Union.<span class="mw-ref" id="cite_ref-39"><a href="#cite_note-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span></p>

<p>In February 2017, Lifmior was approved for use in the European Union.<span class="mw-ref" id="cite_ref-40"><a href="#cite_note-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span> It was withdrawn from the market in February 2020.<span class="mw-ref" id="cite_ref-41"><a href="#cite_note-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span></p>

<p>In June 2017, Erelzi was approved for use in the European Union.<span class="mw-ref" id="cite_ref-42"><a href="#cite_note-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span></p>

<p>In May 2020, Nepexto was approved for use in the European Union.<span class="mw-ref" id="cite_ref-Nepexto_EPAR_43-0"><a href="#cite_note-Nepexto_EPAR-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Similar_agents">Similar agents</h2></summary>
    
<ul><li>Soluble TNF receptor
<ul><li>Pegsunercept</li></ul></li>
<li>Anti-TNF monoclonal antibodies
<ul><li><a href="Infliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Infliximab" title="Infliximab">Infliximab</a></li>
<li><a href="Adalimumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Adalimumab" title="Adalimumab">Adalimumab</a></li>
<li>Certolizumab pegol</li>
<li>Golimumab</li></ul></li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-Drugs.com_pregnancy-1"> <span id="mw-reference-text-cite_note-Drugs.com_pregnancy-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/pregnancy/etanercept.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/pregnancy/etanercept.html'" tppabs="https://www.drugs.com/pregnancy/etanercept.html" class="external text external">"Etanercept Use During Pregnancy"</a>. <i>Drugs.com</i>. 24 January 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">13 August</span> 2020</span>.</cite></span></li><li id="cite_note-titleTNF_defined_as_a_therapeutic_target_for_rheumatoid_arthritis_and_other_autoimmune_diseases_-_Nature_Medicine-2"> <span id="mw-reference-text-cite_note-titleTNF_defined_as_a_therapeutic_target_for_rheumatoid_arthritis_and_other_autoimmune_diseases_-_Nature_Medicine-2" class="mw-reference-text"><cite id="CITEREFFeldmannMaini2003" class="citation journal cs1">Feldmann M, Maini RN (October 2003). "TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases". <i>Nature Medicine</i>. <b>9</b> (10): 1245–50. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnm939  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnm939'" tppabs="https://doi.org/10.1038%2Fnm939" class="external text external">10.1038/nm939</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/14520364  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/14520364'" tppabs="https://pubmed.ncbi.nlm.nih.gov/14520364" class="external text external">14520364</a>. S2CID<span>&nbsp;</span><a href="javascript:if(confirm('https://api.semanticscholar.org/CorpusID:52860838  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://api.semanticscholar.org/CorpusID:52860838'" tppabs="https://api.semanticscholar.org/CorpusID:52860838" class="external text external">52860838</a>.</cite></span></li><li id="cite_note-3"> <span id="mw-reference-text-cite_note-3" class="mw-reference-text"><cite id="CITEREFPeppelCrawfordBeutler1991" class="citation journal cs1">Peppel K, Crawford D, Beutler B (December 1991). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2119031  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2119031'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2119031" class="external text external">"A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity"</a>. <i>The Journal of Experimental Medicine</i>. <b>174</b> (6): 1483–89. doi:<a href="javascript:if(confirm('https://doi.org/10.1084%2Fjem.174.6.1483  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1084%2Fjem.174.6.1483'" tppabs="https://doi.org/10.1084%2Fjem.174.6.1483" class="external text external">10.1084/jem.174.6.1483</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2119031  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2119031'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2119031" class="external text external">2119031</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1660525  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1660525'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1660525" class="external text external">1660525</a>.</cite></span></li><li id="cite_note-4"> <span id="mw-reference-text-cite_note-4" class="mw-reference-text"><cite id="CITEREFPeppelPoltorakMelhadoJirik1993" class="citation journal cs1">Peppel K, Poltorak A, Melhado I, Jirik F, Beutler B (November 1993). "Expression of a TNF inhibitor in transgenic mice". <i>Journal of Immunology</i>. <b>151</b> (10): 5699–703. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/7693816  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/7693816'" tppabs="https://pubmed.ncbi.nlm.nih.gov/7693816" class="external text external">7693816</a>.</cite></span></li><li id="cite_note-5"> <span id="mw-reference-text-cite_note-5" class="mw-reference-text">U.S. Patent number: 5,447,851</span></li><li id="cite_note-title||_DukeMedNews_||_Arthritis_Drug_Effective_for_Depression_in_Psoriasis_Sufferers-6"> <span id="mw-reference-text-cite_note-title||_DukeMedNews_||_Arthritis_Drug_Effective_for_Depression_in_Psoriasis_Sufferers-6" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20071020205003/http://www.dukemednews.org/news/article.php?id=9419  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20071020205003/http://www.dukemednews.org/news/article.php?id=9419'" tppabs="https://web.archive.org/web/20071020205003/http://www.dukemednews.org/news/article.php?id=9419" class="external text external">"Arthritis Drug Effective for Depression in Psoriasis Sufferers"</a>. Archived from <a href="javascript:if(confirm('http://www.dukemednews.org/news/article.php?id=9419  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.dukemednews.org/news/article.php?id=9419'" tppabs="http://www.dukemednews.org/news/article.php?id=9419" class="external text external">the original</a> on 2007-10-20<span class="reference-accessdate">. Retrieved <span class="nowrap">2008-01-10</span></span>.</cite></span></li><li id="cite_note-pmid17389658-7"> <span id="mw-reference-text-cite_note-pmid17389658-7" class="mw-reference-text"><cite id="CITEREFBraunMcHughSinghWajdula2007" class="citation journal cs1">Braun J, McHugh N, Singh A, Wajdula JS, Sato R (June 2007). <a href="javascript:if(confirm('https://doi.org/10.1093/rheumatology/kem069  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093/rheumatology/kem069'" tppabs="https://doi.org/10.1093/rheumatology/kem069" class="external text external">"Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly"</a>. <i>Rheumatology</i>. <b>46</b> (6): 999–1004. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1093%2Frheumatology%2Fkem069  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1093%2Frheumatology%2Fkem069'" tppabs="https://doi.org/10.1093%2Frheumatology%2Fkem069" class="external text external">10.1093/rheumatology/kem069</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17389658  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17389658'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17389658" class="external text external">17389658</a>.</cite></span></li><li id="cite_note-WHO21st-8"> <span id="mw-reference-text-cite_note-WHO21st-8" class="mw-reference-text"><cite id="CITEREFWorld_Health_Organization2019" class="citation book cs1">World Health Organization (2019). <i>World Health Organization model list of essential medicines: 21st list 2019</i>. Geneva: World Health Organization. hdl:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://hdl.handle.net/10665%2F325771  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://hdl.handle.net/10665%2F325771'" tppabs="https://hdl.handle.net/10665%2F325771" class="external text external">10665/325771</a></span>. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.</cite></span></li><li id="cite_note-9"> <span id="mw-reference-text-cite_note-9" class="mw-reference-text"><cite id="CITEREFSiegel1998" class="citation pressrelease cs1">Siegel JP (November 2, 1998). <a href="javascript:if(confirm('https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm088659.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm088659.pdf'" tppabs="https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm088659.pdf" class="external text external">"Approval of Etanercept for treatment of rheumatoid arthritis"</a> <span class="cs1-format">(PDF)</span>. Letter to Sally Gould. Food and Drug Administration<span class="reference-accessdate">. Retrieved <span class="nowrap">April 14,</span> 2015</span>.</cite><span>
</span></span></li><li id="cite_note-10"> <span id="mw-reference-text-cite_note-10" class="mw-reference-text"><cite id="CITEREFWeiss1999" class="citation pressrelease cs1">Weiss, Karen D. (May 27, 1999). <a href="javascript:if(confirm('https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm088844.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm088844.pdf'" tppabs="https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm088844.pdf" class="external text external">"Approval of Etanercept for treatment of polyarticular course juvenile rheumatoid arthritis (JRA)"</a> <span class="cs1-format">(PDF)</span>. Letter to Sally Gould. Food and Drug Administration<span class="reference-accessdate">. Retrieved <span class="nowrap">April 14,</span> 2015</span>.</cite><span>
</span></span></li><li id="cite_note-11"> <span id="mw-reference-text-cite_note-11" class="mw-reference-text"><cite id="CITEREFWeiss2002" class="citation pressrelease cs1">Weiss KD (January 15, 2002). <a href="javascript:if(confirm('http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/etanimm011502L.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/etanimm011502L.htm'" tppabs="http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/etanimm011502L.htm" class="external text external">"Approval of Etanercept for treatment of psoriatic arthritis"</a>. Letter to Sally Gould. Food and Drug Administration<span class="reference-accessdate">. Retrieved <span class="nowrap">April 14,</span> 2015</span>.</cite><span>
</span></span></li><li id="cite_note-12"> <span id="mw-reference-text-cite_note-12" class="mw-reference-text"><cite id="CITEREFKeegan2003" class="citation pressrelease cs1">Keegan P (July 24, 2003). <a href="javascript:if(confirm('http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/103795-5123_Enbrel_approv.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/103795-5123_Enbrel_approv.pdf'" tppabs="http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/103795-5123_Enbrel_approv.pdf" class="external text external">"Approval of Etanercept for treatment of ankylosing spondylitis"</a> <span class="cs1-format">(PDF)</span>. Letter to Douglas Hunt. Food and Drug Administration<span class="reference-accessdate">. Retrieved <span class="nowrap">April 14,</span> 2015</span>.</cite><span>
</span></span></li><li id="cite_note-13"> <span id="mw-reference-text-cite_note-13" class="mw-reference-text"><cite id="CITEREFMaxwellZochlingBoonenSingh2015" class="citation journal cs1">Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, Benkhalti Jandu M, Tugwell P, Wells GA (April 2015). <a href="javascript:if(confirm('http://ecite.utas.edu.au/120128  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://ecite.utas.edu.au/120128'" tppabs="http://ecite.utas.edu.au/120128" class="external text external">"TNF-alpha inhibitors for ankylosing spondylitis"</a>. <i>The Cochrane Database of Systematic Reviews</i>. <b>4</b> (4): CD005468. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD005468.pub2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD005468.pub2'" tppabs="https://doi.org/10.1002%2F14651858.CD005468.pub2" class="external text external">10.1002/14651858.CD005468.pub2</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25887212  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25887212'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25887212" class="external text external">25887212</a>.</cite></span></li><li id="cite_note-14"> <span id="mw-reference-text-cite_note-14" class="mw-reference-text"><cite id="CITEREFWalton2004" class="citation pressrelease cs1">Walton M (April 30, 2004). <a href="javascript:if(confirm('http://www.accessdata.fda.gov/drugsatfda_docs/appletter/biologics/2004/103795_5149ltr.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.accessdata.fda.gov/drugsatfda_docs/appletter/biologics/2004/103795_5149ltr.pdf'" tppabs="http://www.accessdata.fda.gov/drugsatfda_docs/appletter/biologics/2004/103795_5149ltr.pdf" class="external text external">"Approval of Etanercept for treatment of moderate to severe plaque psoriasis"</a> <span class="cs1-format">(PDF)</span>. Letter to Douglas Hunt. Food and Drug Administration<span class="reference-accessdate">. Retrieved <span class="nowrap">April 14,</span> 2015</span>.</cite><span>
</span></span></li><li id="cite_note-Enbrel_EPAR-15"> <span id="mw-reference-text-cite_note-Enbrel_EPAR-15" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/enbrel  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/enbrel'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/enbrel" class="external text external">"Enbrel EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2 April</span> 2020</span>.</cite> Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</span></li><li id="cite_note-Wyeth_and_Amgen-16"> <span id="mw-reference-text-cite_note-Wyeth_and_Amgen-16" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20080505133653/https://money.cnn.com/news/newsfeeds/articles/apwire/21965cf0a650a8b5897142bfcbccb427.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20080505133653/https://money.cnn.com/news/newsfeeds/articles/apwire/21965cf0a650a8b5897142bfcbccb427.htm'" tppabs="https://web.archive.org/web/20080505133653/https://money.cnn.com/news/newsfeeds/articles/apwire/21965cf0a650a8b5897142bfcbccb427.htm" class="external text external">"Wyeth and Amgen heighten warning of life-threatening infections on skin drug Enbrel"</a>. Archived from <a href="javascript:if(confirm('https://money.cnn.com/news/newsfeeds/articles/apwire/21965cf0a650a8b5897142bfcbccb427.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://money.cnn.com/news/newsfeeds/articles/apwire/21965cf0a650a8b5897142bfcbccb427.htm'" tppabs="https://money.cnn.com/news/newsfeeds/articles/apwire/21965cf0a650a8b5897142bfcbccb427.htm" class="external text external">the original</a> on 2008-05-05<span class="reference-accessdate">. Retrieved <span class="nowrap">2008-05-02</span></span>.</cite></span></li><li id="cite_note-FDAReport-17"> <span id="mw-reference-text-cite_note-FDAReport-17" class="mw-reference-text"><cite class="citation conference cs1"><a href="javascript:if(confirm('https://www.fda.gov/ohrms/dockets/ac/01/briefing/3779b2_01_cber_safety%20_revision2.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/ohrms/dockets/ac/01/briefing/3779b2_01_cber_safety%20_revision2.pdf'" tppabs="https://www.fda.gov/ohrms/dockets/ac/01/briefing/3779b2_01_cber_safety%20_revision2.pdf" class="external text external"><i>Safety Update on TNF- α Antagonists: Infliximab and Etanercept</i></a> <span class="cs1-format">(PDF)</span>. Food and Drug Administration. pp.<span>&nbsp;</span>13–14<span class="reference-accessdate">. Retrieved <span class="nowrap">20 December</span> 2013</span>.</cite></span></li><li id="cite_note-titlePrescribing_Information_-_ENBREL-18"> <span id="mw-reference-text-cite_note-titlePrescribing_Information_-_ENBREL-18" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20071014032450/http://enbrel.com/prescribing-information.jsp  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20071014032450/http://enbrel.com/prescribing-information.jsp'" tppabs="https://web.archive.org/web/20071014032450/http://enbrel.com/prescribing-information.jsp" class="external text external">"Prescribing Information – Enbrel"</a>. Archived from <a href="javascript:if(confirm('http://www.enbrel.com/prescribing-information.jsp  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.enbrel.com/prescribing-information.jsp'" tppabs="http://www.enbrel.com/prescribing-information.jsp" class="external text external">the original</a> on 2007-10-14<span class="reference-accessdate">. Retrieved <span class="nowrap">2008-01-10</span></span>.</cite></span></li><li id="cite_note-19"> <span id="mw-reference-text-cite_note-19" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.uptodate.com/contents/strongyloidiasis/abstract/67?utdPopup=true  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.uptodate.com/contents/strongyloidiasis/abstract/67?utdPopup=true'" tppabs="http://www.uptodate.com/contents/strongyloidiasis/abstract/67?utdPopup=true" class="external text external">"UpToDate"</a>.</cite></span></li><li id="cite_note-20"> <span id="mw-reference-text-cite_note-20" class="mw-reference-text"><cite id="CITEREFZalevskySecherEzhevskyJanot2007" class="citation journal cs1">Zalevsky J, Secher T, Ezhevsky SA, Janot L, Steed PM, O'Brien C, Eivazi A, Kung J, Nguyen DH, Doberstein SK, Erard F, Ryffel B, Szymkowski DE (August 2007). <a href="javascript:if(confirm('https://doi.org/10.4049/jimmunol.179.3.1872  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4049/jimmunol.179.3.1872'" tppabs="https://doi.org/10.4049/jimmunol.179.3.1872" class="external text external">"Dominant-negative inhibitors of soluble TNF attenuate experimental arthritis without suppressing innate immunity to infection"</a>. <i>Journal of Immunology</i>. <b>179</b> (3): 1872–83. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.4049%2Fjimmunol.179.3.1872  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4049%2Fjimmunol.179.3.1872'" tppabs="https://doi.org/10.4049%2Fjimmunol.179.3.1872" class="external text external">10.4049/jimmunol.179.3.1872</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17641054  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17641054'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17641054" class="external text external">17641054</a>.</cite></span></li><li id="cite_note-pmid16135466-21"> <span id="mw-reference-text-cite_note-pmid16135466-21" class="mw-reference-text"><cite id="CITEREFMadhusudanMuthuramalingamBraybrookeWilner2005" class="citation journal cs1">Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, Ganesan TS (September 2005). "Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer". <i>Journal of Clinical Oncology</i>. <b>23</b> (25): 5950–59. doi:<a href="javascript:if(confirm('https://doi.org/10.1200%2FJCO.2005.04.127  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1200%2FJCO.2005.04.127'" tppabs="https://doi.org/10.1200%2FJCO.2005.04.127" class="external text external">10.1200/JCO.2005.04.127</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16135466  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16135466'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16135466" class="external text external">16135466</a>.</cite></span></li><li id="cite_note-pmid1936291-22"> <span id="mw-reference-text-cite_note-pmid1936291-22" class="mw-reference-text"><cite id="CITEREFSmolaSoyerScharnagl1991" class="citation journal cs1">Smola MG, Soyer HP, Scharnagl E (October 1991). "Surgical treatment of dermatofibrosarcoma protuberans. A retrospective study of 20 cases with review of literature". <i>European Journal of Surgical Oncology</i>. <b>17</b> (5): 447–53. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1936291  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1936291'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1936291" class="external text external">1936291</a>.</cite></span></li><li id="cite_note-23"> <span id="mw-reference-text-cite_note-23" class="mw-reference-text"><cite id="CITEREFHouelHilliardYuMcLoughlin2014" class="citation journal cs1">Houel S, Hilliard M, Yu YQ, McLoughlin N, Martin SM, Rudd PM, Williams JP, Chen W (January 2014). "N- and O-glycosylation analysis of etanercept using liquid chromatography and quadrupole time-of-flight mass spectrometry equipped with electron-transfer dissociation functionality". <i>Analytical Chemistry</i>. <b>86</b> (1): 576–84. doi:<a href="javascript:if(confirm('https://doi.org/10.1021%2Fac402726h  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1021%2Fac402726h'" tppabs="https://doi.org/10.1021%2Fac402726h" class="external text external">10.1021/ac402726h</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24308717  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24308717'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24308717" class="external text external">24308717</a>.</cite></span></li><li id="cite_note-24"> <span id="mw-reference-text-cite_note-24" class="mw-reference-text"><cite id="CITEREFMukaiNakamuraYoshikawaYoshioka2010" class="citation journal cs1">Mukai Y, Nakamura T, Yoshikawa M, Yoshioka Y, Tsunoda S, Nakagawa S, Yamagata Y, Tsutsumi Y (November 2010). "Solution of the structure of the TNF-TNFR2 complex". <i>Science Signaling</i>. <b>3</b> (148): ra83. doi:<a href="javascript:if(confirm('https://doi.org/10.1126%2Fscisignal.2000954  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1126%2Fscisignal.2000954'" tppabs="https://doi.org/10.1126%2Fscisignal.2000954" class="external text external">10.1126/scisignal.2000954</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21081755  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21081755'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21081755" class="external text external">21081755</a>.</cite></span></li><li id="cite_note-:0-25"> <span id="mw-reference-text-cite_note-:0-25" class="mw-reference-text"><cite id="CITEREFLamannaMayerRupprechterFuchs2017" class="citation journal cs1">Lamanna WC, Mayer RE, Rupprechter A, Fuchs M, Higel F, Fritsch C, Vogelsang C, Seidl A, Toll H, Schiestl M, Holzmann J (June 2017). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479810  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479810'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479810" class="external text external">"The structure-function relationship of disulfide bonds in etanercept"</a>. <i>Scientific Reports</i>. <b>7</b> (1): 3951. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/2017NatSR...7.3951L  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/2017NatSR...7.3951L'" tppabs="https://ui.adsabs.harvard.edu/abs/2017NatSR...7.3951L" class="external text external">2017NatSR...7.3951L</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fs41598-017-04320-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fs41598-017-04320-5'" tppabs="https://doi.org/10.1038%2Fs41598-017-04320-5" class="external text external">10.1038/s41598-017-04320-5</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479810  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479810'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5479810" class="external text external">5479810</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28638112  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28638112'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28638112" class="external text external">28638112</a>.</cite></span></li><li id="cite_note-26"> <span id="mw-reference-text-cite_note-26" class="mw-reference-text"><cite id="CITEREFNorman2017" class="citation journal cs1">Norman, Peter (February 16, 2017). "Enbrel and etanercept biosimilars: a tale of two patent system". <i>Pharmaceutical Patent Analyst</i>. <b>6</b> (1): 5–7. doi:<a href="javascript:if(confirm('https://doi.org/10.4155%2Fppa-2016-0043  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4155%2Fppa-2016-0043'" tppabs="https://doi.org/10.4155%2Fppa-2016-0043" class="external text external">10.4155/ppa-2016-0043</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/28201948  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/28201948'" tppabs="https://pubmed.ncbi.nlm.nih.gov/28201948" class="external text external">28201948</a>.</cite></span></li><li id="cite_note-27"> <span id="mw-reference-text-cite_note-27" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20170118085127/https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080536.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20170118085127/https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080536.htm'" tppabs="https://web.archive.org/web/20170118085127/https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080536.htm" class="external text external">"Etanercept Product Approval Information - Licensing Action 12/2/98"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 1 April 2016. Archived from <a href="javascript:if(confirm('https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080536.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080536.htm'" tppabs="https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080536.htm" class="external text external">the original</a> on 18 January 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">4 June</span> 2020</span>.</cite></span></li><li id="cite_note-28"> <span id="mw-reference-text-cite_note-28" class="mw-reference-text"><a href="javascript:if(confirm('http://seattletimes.com/html/health/2008120449_drugs18m.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://seattletimes.com/html/health/2008120449_drugs18m.html'" tppabs="http://seattletimes.com/html/health/2008120449_drugs18m.html" class="external text external">"What's behind the whopping price tags on the newest generation of drugs:</a> The story behind the production of Enbrel, Amgen's popular rheumatoid arthritis drug, provides insights as to why bioengineered drugs are so expensive."  Carol M. Ostrom, Seattle Times, August 18, 2008</span></li><li id="cite_note-NYTAmgen2011-29"> <span id="mw-reference-text-cite_note-NYTAmgen2011-29" class="mw-reference-text"><a href="javascript:if(confirm('https://www.nytimes.com/2011/11/23/business/amgens-new-enbrel-patent-may-undercut-health-care-plan.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.nytimes.com/2011/11/23/business/amgens-new-enbrel-patent-may-undercut-health-care-plan.html'" tppabs="https://www.nytimes.com/2011/11/23/business/amgens-new-enbrel-patent-may-undercut-health-care-plan.html" class="external text external">"Patent for Amgen Drug May Undercut Health Care Plan"</a>, Andrew Pollock, New York Times, November 23, 2011</span></li><li id="cite_note-30"> <span id="mw-reference-text-cite_note-30" class="mw-reference-text"><a href="javascript:if(confirm('http://bostonherald.com/news/columnists/view/2011_1103painful_reality  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://bostonherald.com/news/columnists/view/2011_1103painful_reality'" tppabs="http://bostonherald.com/news/columnists/view/2011_1103painful_reality" class="external text external">"Co-pay hike a painful reality; Miracle drug monthly cost jumps from $42 to $600"</a>, Margery Eagan, Boston Herald, November 3, 2011</span></li><li id="cite_note-IFHP2013-31"> <span id="mw-reference-text-cite_note-IFHP2013-31" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://static1.squarespace.com/static/518a3cfee4b0a77d03a62c98/t/534fc9ebe4b05a88e5fbab70/1397737963288/2013+iFHP+FINAL+4+14+14.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://static1.squarespace.com/static/518a3cfee4b0a77d03a62c98/t/534fc9ebe4b05a88e5fbab70/1397737963288/2013+iFHP+FINAL+4+14+14.pdf'" tppabs="https://static1.squarespace.com/static/518a3cfee4b0a77d03a62c98/t/534fc9ebe4b05a88e5fbab70/1397737963288/2013+iFHP+FINAL+4+14+14.pdf" class="external text external">"2013 Comparative Price Report"</a> <span class="cs1-format">(PDF)</span>. International Federation of Health Plans<span class="reference-accessdate">. Retrieved <span class="nowrap">24 November</span> 2017</span>.</cite></span></li><li id="cite_note-32"> <span id="mw-reference-text-cite_note-32" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.sec.gov/Archives/edgar/data/78003/000119312511048877/dex13.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.sec.gov/Archives/edgar/data/78003/000119312511048877/dex13.htm'" tppabs="https://www.sec.gov/Archives/edgar/data/78003/000119312511048877/dex13.htm" class="external text external">"Portions of the 2010 Financial Report"</a>. Sec.gov<span class="reference-accessdate">. Retrieved <span class="nowrap">2019-06-05</span></span>.</cite></span></li><li id="cite_note-33"> <span id="mw-reference-text-cite_note-33" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.uspto.gov/patents/resources/terms/156.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.uspto.gov/patents/resources/terms/156.html'" tppabs="http://www.uspto.gov/patents/resources/terms/156.html" class="external text external">"Patent Terms Extended Under 35 USC §156"</a>.</cite></span></li><li id="cite_note-34"> <span id="mw-reference-text-cite_note-34" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.gabionline.net/Biosimilars/News/New-Amgen-Enbrel-patent-could-block-biosimilars-until-2028  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.gabionline.net/Biosimilars/News/New-Amgen-Enbrel-patent-could-block-biosimilars-until-2028'" tppabs="http://www.gabionline.net/Biosimilars/News/New-Amgen-Enbrel-patent-could-block-biosimilars-until-2028" class="external text external">"New Amgen Enbrel patent could block biosimilars until 2028"</a>. 2011-11-25<span class="reference-accessdate">. Retrieved <span class="nowrap">2019-07-14</span></span>.</cite></span></li><li id="cite_note-35"> <span id="mw-reference-text-cite_note-35" class="mw-reference-text"><cite id="CITEREFKaldre2008" class="citation web cs1">Kaldre I (2008). <a href="javascript:if(confirm('https://scholarship.law.duke.edu/cgi/viewcontent.cgi?referer=https://en.wikipedia.org/&httpsredir=1&article=1184&context=dltr  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://scholarship.law.duke.edu/cgi/viewcontent.cgi?referer=https://en.wikipedia.org/&httpsredir=1&article=1184&context=dltr'" tppabs="https://scholarship.law.duke.edu/cgi/viewcontent.cgi?referer=https://en.wikipedia.org/&httpsredir=1&article=1184&context=dltr" class="external text external">"The Future of Generic Biologics: Should the United States "Follow-On" the European Pathway?"</a>. <i>www.law.duke.edu</i><span class="reference-accessdate">. Retrieved <span class="nowrap">2019-06-05</span></span>.</cite></span></li><li id="cite_note-36"> <span id="mw-reference-text-cite_note-36" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.cipla.com/CiplaSite/Media/PDF/News-Archives/Press-Release-Launch-of-first-biosimilar-of-Etanercept-in-India.pdf?ext=.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.cipla.com/CiplaSite/Media/PDF/News-Archives/Press-Release-Launch-of-first-biosimilar-of-Etanercept-in-India.pdf?ext=.pdf'" tppabs="http://www.cipla.com/CiplaSite/Media/PDF/News-Archives/Press-Release-Launch-of-first-biosimilar-of-Etanercept-in-India.pdf?ext=.pdf" class="external text external">"Cipla - Home"</a> <span class="cs1-format">(PDF)</span>. Cipla.com<span class="reference-accessdate">. Retrieved <span class="nowrap">2019-06-05</span></span>.</cite></span></li><li id="cite_note-37"> <span id="mw-reference-text-cite_note-37" class="mw-reference-text"><a href="javascript:if(confirm('http://www.gabionline.net/Biosimilars/News/Biosimilar-etanercept-submitted-for-approval-in-EU  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.gabionline.net/Biosimilars/News/Biosimilar-etanercept-submitted-for-approval-in-EU'" tppabs="http://www.gabionline.net/Biosimilars/News/Biosimilar-etanercept-submitted-for-approval-in-EU" class="external text external">Biosimilar etanercept submitted for approval in EU</a> GaBI Online – Generics and Biosimilars Initiative (Jan 2015). Retrieved 13 July 2016.</span></li><li id="cite_note-38"> <span id="mw-reference-text-cite_note-38" class="mw-reference-text"><a href="javascript:if(confirm('https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM510493.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM510493.pdf'" tppabs="https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM510493.pdf" class="external text external">FDA Briefing Document Arthritis Advisory Committee Meeting July 13, 2016</a>. FDA AAC Brief. BLA 761042, GP2015, a proposed biosimilar to Enbrel. Retrieved 13 July 2016.</span></li><li id="cite_note-39"> <span id="mw-reference-text-cite_note-39" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/benepali  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/benepali'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/benepali" class="external text external">"Benpali EPAR"</a>. <i>European Medicines Agency (EMA)</i>. 17 September 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">2 April</span> 2020</span>.</cite></span></li><li id="cite_note-40"> <span id="mw-reference-text-cite_note-40" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/lifmior  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/lifmior'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/lifmior" class="external text external">"Lifmior EPAR"</a>. <i>European Medicines Agency (EMA)</i>. 17 September 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">2 April</span> 2020</span>.</cite></span></li><li id="cite_note-41"> <span id="mw-reference-text-cite_note-41" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/documents/public-statement/public-statement-lifmior-withdrawal-marketing-authorisation-european-union_en.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/documents/public-statement/public-statement-lifmior-withdrawal-marketing-authorisation-european-union_en.pdf'" tppabs="https://www.ema.europa.eu/documents/public-statement/public-statement-lifmior-withdrawal-marketing-authorisation-european-union_en.pdf" class="external text external">"Public statement on Lifmior: Withdrawal of the marketing authorisation in the European Union"</a> <span class="cs1-format">(PDF)</span><span class="reference-accessdate">. Retrieved <span class="nowrap">2 April</span> 2020</span>.</cite></span></li><li id="cite_note-42"> <span id="mw-reference-text-cite_note-42" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/erelzi  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/erelzi'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/erelzi" class="external text external">"Erelzi EPAR"</a>. <i>European Medicines Agency (EMA)</i>. 17 September 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">2 April</span> 2020</span>.</cite></span></li><li id="cite_note-Nepexto_EPAR-43"> <span id="mw-reference-text-cite_note-Nepexto_EPAR-43" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/nepexto  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/nepexto'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/nepexto" class="external text external">"Nepexto EPAR"</a>. <i>European Medicines Agency (EMA)</i>. 24 March 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">4 June</span> 2020</span>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<table role="presentation" class="mbox-small  sistersitebox" style="background-color:#f9f9f9;border:1px solid #aaa;color:#000">
<tbody><tr>
<td class="mbox-image"><figure-inline class="noviewer"><span><img src="../I/m/Commons-logo.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Commons-logo.svg.png" data-file-width="1024" data-file-height="1376" data-file-type="drawing" height="40" width="30"></span></figure-inline></td>
<td class="mbox-text plainlist">Wikimedia Commons has media related to <i><b><a href="javascript:if(confirm('https://commons.wikimedia.org/wiki/Category:Etanercept  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://commons.wikimedia.org/wiki/Category:Etanercept'" tppabs="https://commons.wikimedia.org/wiki/Category:Etanercept" title="commons:Category:Etanercept" class="external"><span style=" ">Etanercept</span></a></b></i>.</td></tr>
</tbody></table>
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/etanercept  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/etanercept'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/etanercept" class="external text external">"Etanercept"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Immunosuppressive_drugs_/_Immunosuppressants_(L04)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Immunosuppressive_drugs_/_Immunosuppressants_(L04)" style="font-size:114%;margin:0 4em">Immunosuppressive drugs<span>&nbsp;</span>/ Immunosuppressants (L04)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Intracellular<br>(initiation)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Antimetabolites</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>purine synthesis inhibitors</i>
<ul><li><a href="Azathioprine.htm" tppabs="https://ptable.com/wiki/compounds/A/Azathioprine" title="Azathioprine">Azathioprine</a></li>
<li><a href="Mycophenolic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Mycophenolic_acid" title="Mycophenolic acid">Mycophenolic acid</a></li></ul></li></ul>

<ul><li><i>pyrimidine synthesis inhibitors</i>
<ul><li><a href="Leflunomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Leflunomide" title="Leflunomide">Leflunomide</a></li>
<li>Teriflunomide</li></ul></li></ul>

<ul><li><i>antifolate</i>
<ul><li><a href="Methotrexate.htm" tppabs="https://ptable.com/wiki/compounds/A/Methotrexate" title="Methotrexate">Methotrexate</a></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Macrolides/<br>other <a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">IL-2</a> inhibitors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>FKBP/Cyclophilin/Calcineurin</i>
<ul><li><a href="Tacrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Tacrolimus" title="Tacrolimus">Tacrolimus</a></li>
<li><a href="Ciclosporin.htm" tppabs="https://ptable.com/wiki/compounds/A/Ciclosporin" title="Ciclosporin">Ciclosporin</a></li>
<li><a href="Pimecrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Pimecrolimus" title="Pimecrolimus">Pimecrolimus</a></li></ul></li></ul>

<ul><li>Abetimus</li>
<li>Gusperimus</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">IMiDs</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Lenalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Lenalidomide" title="Lenalidomide">Lenalidomide</a></li>
<li>Pomalidomide</li>
<li><a href="Thalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Thalidomide" title="Thalidomide">Thalidomide</a></li>
<li><i>PDE4 inhibitor</i>
<ul><li>Apremilast</li></ul></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Intracellular<br>(reception)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">IL-1 receptor antagonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Anakinra.htm" tppabs="https://ptable.com/wiki/compounds/A/Anakinra" title="Anakinra">Anakinra</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">mTOR</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Sirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Sirolimus" title="Sirolimus">Sirolimus</a></li>
<li><a href="Everolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Everolimus" title="Everolimus">Everolimus</a></li>
<li>Ridaforolimus</li>
<li><a href="Temsirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Temsirolimus" title="Temsirolimus">Temsirolimus</a></li>
<li>Umirolimus</li>
<li>Zotarolimus</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Extracellular</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Antibody.htm" tppabs="https://ptable.com/wiki/compounds/A/Antibody" title="Antibody">Antibodies</a></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Monoclonal</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Serum target<br>(noncellular)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Complement component 5</i>
<ul><li>Eculizumab</li></ul></li>
<li><i>TNF</i>
<ul><li><a href="Adalimumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Adalimumab" title="Adalimumab">Adalimumab</a></li>
<li>Afelimomab</li>
<li>Certolizumab pegol</li>
<li>Golimumab</li>
<li><a href="Infliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Infliximab" title="Infliximab">Infliximab</a></li>
<li>Nerelimomab</li></ul></li>
<li><i>Interleukin 5</i>
<ul><li>Mepolizumab</li></ul></li>
<li><i>Immunoglobulin E</i>
<ul><li><a href="Omalizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Omalizumab" title="Omalizumab">Omalizumab</a></li></ul></li></ul>

<ul><li><i>Interferon</i>
<ul><li>Faralimomab</li></ul></li></ul>

<ul><li><i>IL-6</i>
<ul><li>Elsilimomab</li></ul></li></ul>

<ul><li><i>IL-12 and IL-23</i>
<ul><li>Lebrikizumab</li>
<li>Ustekinumab</li></ul></li></ul>

<ul><li><i>IL-17A</i>
<ul><li>Secukinumab</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Cellular<br>target</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>CD3</i>
<ul><li><a href="Muromonab-CD3.htm" tppabs="https://ptable.com/wiki/compounds/A/Muromonab-CD3" title="Muromonab-CD3">Muromonab-CD3</a></li>
<li>Otelixizumab</li>
<li>Teplizumab</li>
<li>Visilizumab</li></ul></li>
<li><i>CD4</i>
<ul><li>Clenoliximab</li>
<li>Keliximab</li>
<li>Zanolimumab</li></ul></li>
<li><i>CD11a</i>
<ul><li>Efalizumab</li></ul></li>
<li><i>CD18</i>
<ul><li>Erlizumab</li></ul></li>
<li><i>CD20</i>
<ul><li>Obinutuzumab</li>
<li><a href="Rituximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Rituximab" title="Rituximab">Rituximab</a></li>
<li>Ocrelizumab</li>
<li>Pascolizumab</li></ul></li>
<li><i>CD23</i>
<ul><li>Gomiliximab</li>
<li>Lumiliximab</li></ul></li>
<li><i>CD40</i>
<ul><li>Teneliximab</li>
<li>Toralizumab</li></ul></li>
<li><i>CD62L/L-selectin</i>
<ul><li>Aselizumab</li></ul></li>
<li><i>CD80</i>
<ul><li>Galiximab</li></ul></li>
<li><i>CD147/Basigin</i>
<ul><li>Gavilimomab</li></ul></li>
<li><i>CD154</i>
<ul><li>Ruplizumab</li></ul></li></ul>

<ul><li><i>BLyS</i>
<ul><li>Belimumab</li>
<li>Blisibimod</li></ul></li>
<li><i>CTLA-4</i>
<ul><li>Ipilimumab</li>
<li>Tremelimumab</li></ul></li>
<li><i>CAT</i>
<ul><li>Bertilimumab</li>
<li>Lerdelimumab</li>
<li>Metelimumab</li></ul></li>
<li><i>Integrin</i>
<ul><li>Natalizumab</li>
<li>Vedolizumab</li></ul></li>
<li><i>Interleukin-6 receptor</i>
<ul><li>Tocilizumab</li></ul></li>
<li><i>LFA-1</i>
<ul><li>Odulimomab</li></ul></li></ul>

<ul><li><i>IL-2 receptor/CD25</i>
<ul><li><a href="Basiliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Basiliximab" title="Basiliximab">Basiliximab</a></li>
<li><a href="Daclizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Daclizumab" title="Daclizumab">Daclizumab</a></li>
<li>Inolimomab</li></ul></li></ul>

<ul><li><i>T-lymphocyte</i> (Zolimomab aritox)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Unsorted</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Atorolimumab</li>
<li>Cedelizumab</li>
<li>Fontolizumab</li>
<li>Maslimomab</li>
<li>Morolimumab</li>
<li>Pexelizumab</li>
<li>Reslizumab</li>
<li>Rovelizumab</li>
<li>Siplizumab</li>
<li>Talizumab</li>
<li>Telimomab aritox</li>
<li>Vapaliximab</li>
<li>Vepalimomab</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Polyclonal</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Anti-thymocyte globulin</li>
<li>Anti-lymphocyte globulin</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">-cept (Fusion)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>CTLA-4</i>
<ul><li>Abatacept</li>
<li>Belatacept</li></ul></li>
<li><i>TNF inhibitor</i>
<ul><li><a href="Etanercept.htm" tppabs="https://ptable.com/wiki/compounds/A/Etanercept" title="Etanercept">Etanercept</a></li>
<li>Pegsunercept</li></ul></li>
<li>Aflibercept</li>
<li><a href="Alefacept.htm" tppabs="https://ptable.com/wiki/compounds/A/Alefacept" title="Alefacept">Alefacept</a></li>
<li>Rilonacept</li></ul>
</div></td></tr></tbody></table><div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Cytokine_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Cytokine_receptor_modulators" style="font-size:114%;margin:0 4em">Cytokine receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Chemokine</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">CSF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Erythropoietin</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">ARA-290</span></li>
<li><span class="new">Asialo erythropoietin</span></li>
<li><span class="new">Carbamylated erythropoietin</span></li>
<li><span class="new">CNTO-530</span></li>
<li><a href="Darbepoetin_alfa.htm" tppabs="https://ptable.com/wiki/compounds/A/Darbepoetin_alfa" title="Darbepoetin alfa">Darbepoetin alfa</a></li>
<li><a href="Epoetin_alfa.htm" tppabs="https://ptable.com/wiki/compounds/A/Epoetin_alfa" title="Epoetin alfa">Epoetin alfa</a></li>
<li>Epoetin beta</li>
<li><span class="new">Epoetin delta</span></li>
<li><span class="new">Epoetin epsilon</span></li>
<li><span class="new">Epoetin gamma</span></li>
<li><span class="new">Epoetin kappa</span></li>
<li><span class="new">Epoetin omega</span></li>
<li><span class="new">Epoetin theta</span></li>
<li>Epoetin zeta</li>
<li>Erythropoietin (EPO)</li>
<li><span class="new">Erythropoietin-Fc</span></li>
<li>Methoxy polyethylene glycol-epoetin beta (CERA/Mircera)</li>
<li>Peginesatide</li>
<li><span class="new">Pegol sihematide (EPO-018B)</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">G-CSF (CSF3)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <a href="Filgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Filgrastim" title="Filgrastim">Filgrastim</a></li>
<li>Granulocyte colony-stimulating factor</li>
<li>Lenograstim</li>
<li><span class="new">Leridistim</span></li>
<li>Lipegfilgrastim</li>
<li><span class="new">Nartograstim</span></li>
<li><a href="Pegfilgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Pegfilgrastim" title="Pegfilgrastim">Pegfilgrastim</a></li>
<li><span class="new">Pegnartograstim</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">GM-CSF (CSF2)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Ecogramostim</span></li>
<li>Granulocyte macrophage colony-stimulating factor</li>
<li><span class="new">Milodistim</span></li>
<li>Molgramostim</li>
<li><span class="new">Regramostim</span></li>
<li><a href="Sargramostim.htm" tppabs="https://ptable.com/wiki/compounds/A/Sargramostim" title="Sargramostim">Sargramostim</a></li></ul>

<ul><li><i>Antibodies:</i> Mavrilimumab</li>
<li>Namilumab</li>
<li>Otilimab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">M-CSF (CSF1)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Cilmostim</span></li>
<li>Interleukin-34</li>
<li><span class="new">Lanimostim</span></li>
<li>Macrophage colony-stimulating factor</li>
<li><span class="new">Mirimostim</span></li></ul>

<ul><li><i>Kinase inhibitors:</i> <span class="new">Agerafenib</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">SCF (c-Kit)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Thrombopoietin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Eltrombopag</li>
<li><span class="new">Pegacaristim</span></li>
<li>Promegapoietin</li>
<li>Romiplostim</li>
<li>Thrombopoietin (THPO, MGDF)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Interferon</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IFNAR (α/β, I)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Albinterferon</li>
<li>Interferon alpha (interferon alfa, IFN-α)</li>
<li>Interferon alfa (IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21)</li>
<li><span class="new">Interferon alfa 2a</span></li>
<li>Interferon alfa 2b</li>
<li><span class="new">Interferon alfa n1</span></li>
<li><a href="Interferon_alfacon-1.htm" tppabs="https://ptable.com/wiki/compounds/A/Interferon_alfacon-1" title="Interferon alfacon-1">Interferon alfacon-1</a></li>
<li>Interferon alpha-n3</li>
<li>Interferon beta (IFN-β) (IFNB1, <span class="new">IFNB3</span>)</li>
<li>Interferon beta 1a</li>
<li>Interferon beta 1b</li>
<li>Interferon kappa (IFN-ε/κ/τ/ζ, IFNK)</li>
<li>Interferon omega (IFN-ω, IFNW1)</li>
<li>Peginterferon alfa-2a</li>
<li>Peginterferon alfa-2b</li></ul>

<ul><li><i>Antibodies:</i> Anifrolumab</li>
<li>Faralimomab</li>
<li><span class="new">MEDI-545</span></li>
<li>Rontalizumab</li>
<li>Sifalimumab</li></ul>

<ul><li><i>Decoy receptors:</i> <span class="new">Bifarcept</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IFNGR (γ, II)</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> Interferon gamma (IFN-γ)</li>
<li><span class="new">Interferon gamma 1b</span></li></ul>

<ul><li><i>Antibodies:</i> Emapalumab</li>
<li>Fontolizumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">IFNLR (λ, III)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See IL-28R (IFNLR) here instead.</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Interleukin</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TGFβ</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">TNF</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK<br><small>(inhibitors)</small></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK1</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Baricitinib</li>
<li>Filgotinib</li>
<li>Momelotinib</li>
<li>Oclacitinib</li>
<li>Ruxolitinib</li>
<li>Tofacitinib (tasocitinib, CP-690550)</li>
<li>Upadacitinib</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK2</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><span class="new">AG-490</span></li>
<li>Atiprimod</li>
<li><span class="new">AZD-1480</span></li>
<li>Baricitinib</li>
<li><span class="new">CHZ868</span></li>
<li>Cucurbitacin I (elatericin B, JSI-124)</li>
<li>CYT387</li>
<li>Lestaurtinib</li>
<li><span class="new">NSC-7908</span></li>
<li><span class="new">NSC-33994</span></li>
<li>Pacritinib</li>
<li>Ruxolitinib</li>
<li><span class="new">SD-1008</span></li>
<li>Tofacitinib (tasocitinib, CP-690550)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">JAK3</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><span class="new">AG-490</span></li>
<li><span class="new">Cercosporamide</span></li>
<li>Decernotinib (VX-509)</li>
<li><span class="new">TCS-21311</span></li>
<li>Tofacitinib (tasocitinib, CP-690550)</li>
<li><span class="new">WHI-P 154</span></li>
<li><span class="new">ZM-39923</span></li>
<li><span class="new">ZM-449829</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Additional cytokines:</i> Cardiotrophin 1 (CT-1)</li>
<li>FMS-like tyrosine kinase 3 ligand (FLT3L)</li>
<li>Leukemia/leukocyte inhibitory factor (LIF)</li>
<li>Oncostatin M (OSM)</li>
<li>Thymic stromal lymphopoietin (TSLP)</li></ul>

<ul><li><i>Additional cytokine receptor modulators:</i> <span class="new">Emfilermin</span></li>
<li>Lestaurtinib</li>
<li>Midostaurin</li>
<li>Quizartinib</li>
<li><a href="Sorafenib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sorafenib" title="Sorafenib">Sorafenib</a></li>
<li><a href="Sunitinib.htm" tppabs="https://ptable.com/wiki/compounds/A/Sunitinib" title="Sunitinib">Sunitinib</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd><i>Receptor/signaling modulators</i></dd>
<dd><i>Signaling peptide/protein receptor modulators</i></dd>
<dd><i>Growth factor receptor modulators</i></dd></dl>
</div></td></tr></tbody></table></div>









<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>